The Otsuka Group comprises 153 companies and employs approximately 36,000 people in 23 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned US $9.6 billion in annual revenue in its fiscal year ended in March 2009.
In 2007, GW entered into a strategic alliance with Otsuka which comprised two separate agreements – a Sativex US licence and a global cannabinoid research collaboration.
Under the Sativex US licence agreement, GW has granted Otsuka an exclusive license to develop and market Sativex in the US. GW is responsible for the manufacture and supply of Sativex to Otsuka. GW and Otsuka jointly oversee all US clinical development and regulatory activities. Such activities are being carried out by GW at Otsuka’s cost.
Under the research collaboration agreement, senior scientists from both GW and Otsuka are directing research into a range of GW cannabinoids as drug candidates within CNS and oncology.
The intention of the collaboration is for Otsuka to select the most promising candidates for full clinical development, regulatory approval and global commercialization. Products selected for full development will be the subject of a license from GW. Under the terms of each product license, Otsuka will fund the global development and commercialization of such products, and GW will receive license fees, milestone payments and a long term commercial supply price and royalty. The financial terms of each license are to be agreed at the time of selection of each product for global development.
Novartis is one of the world’s leading pharmaceutical companies. In 2010, Novartis Group's continuing operations achieved net sales of USD 50.6 billion. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 119,000 full-time-equivalent associates and operate in more than 140 countries around the world.
GW has entered into an exclusive licence agreement for Novartis to commercialise Sativex in Australia and New Zealand, Asia (excluding Japan, China and Hong Kong), Middle East (excluding Israel/Palestine) and Africa. Under the terms of the agreement, Novartis has exclusive commercialisation rights to Sativex and will act as Marketing Authorisation holder for Sativex. GW will be responsible for the manufacture and supply of Sativex to Novartis.
Almirall is Spain’s largest pharmaceutical company with sales approximating €1 billion. The company has a significant presence in Spain, where it is number two by market share, and has 11 subsidiary operations in other major European markets, including France, Germany, Italy, UK, Portugal and Belgium, as well as in Latin America.
In December 2005, GW and Almirall entered into a licence agreement, whereby GW granted Almirall an exclusive license to market Sativex in the European Union (excluding the UK), EU accession countries as well as Switzerland, Norway and Turkey. GW is responsible for the manufacture and supply of Sativex to Almirall.
In March 2012, GW signed an amendment to its Sativex licence agreement with Almirall; as part of the revised agreement, Almirall has been granted rights to market Sativex in Mexico.
Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry. The pharmaceuticals business operates under the name Bayer Schering Pharma. This business employs 38,000 people and reported 2007 sales of €10.3bn.
In 2003, GW and Bayer entered into a licence agreement, whereby GW granted Bayer an exclusive license to market Sativex in the UK and Canada. GW is responsible for the manufacture and supply of Sativex to Bayer.